Aptose Biosciences — Investor Presentation (January 2023)
36 slides from Aptose Biosciences's investor presentation, Jan 6, 2023
Slide 1: Aptose Corporate Presentation January 2023
P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W Aptose Corporate Presentation January 2023 NASDAQ: APTO TSX: APS I n c o r p o r a t i n g c l i n i c a l d a t a f r o m 2 0 2 2 A S H A n n u a l M e e t i n g
Slide 2: Disclosure
Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of
Slide 3: Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Hematologic Malignancies
Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Life - threatening Hematologic Malignancies Expect near term value creation as monotherapy in deep R/R AML populations of high unmet need Expect long term value creation as ideal TKI for doublet/triplet combination therapy in 1L/2
Slide 4: Why Tuspetinib Can Address the Greatest Needs of AML Patients
Tuspetinib Treats AML Disease Heterogeneity 4 Why We Believe Tuspetinib Can Address the Greatest Needs of AML Patients and Achieve ≥ $1B Commercial Success
Slide 5: Targets Clinically Validated Kinases in Oncogenic Signaling Pathways
Tuspetinib Targets Clinically Validated Kinases in Oncogenic Signaling Pathways Growth Factor Receptors C - KIT MUT JAK PI3K Ras RSK AKT S6K PI3K / AKT / mTOR / S6K pathway MAPK / ERK pathway mTOR Cell Growth and Proliferation SYK STAT STAT JAK RAF MEK ERK NPM1c MUT Excessive levels of FLT3 ligand b
Slide 6: Creating Near Term Value: Ideal TKI Monotherapy for Accelerated Approval in R/R AML
Tuspetinib Creating Near Term Value Ideal TKI Monotherapy for Accelerated Approval in R/R AML Who Failed Prior FLT3i Tuspetinib Accelerated Development May Offer x Value creation in 2023 and beyond x First approval in AML indication x Well tolerated therapy x Bridge to stem cell transplant x Longer
Slide 7: Creating Near and Long Term Value: Triplet Therapy in 1L AML
Tuspetinib Creating Near Term and Long Term Value Tuspetinib Ideal Safe and Broadly Active TKI for Triplet Therapy in 1L AML HMA Hypomethylating Agent Accelerated Proliferation Altered Gene Expression Avoid Cell Death Venetoclax BCL - 2 inhibitor FLT3i - TKI that Inhibits Proliferation Pathways Canc
Slide 8: US Sales Potential in AML Could Reach ≥ $1B
Tuspetinib US Sales Potential in AML Could Reach ≥ $ 1B Potential Annual Sales ≥ $1 B PRIOR FLT3 INHIBITOR FAILURES Superior Monotherapy for Accelerated Approval MAINTENANCE THERAPY Maintain Patients Long Term MRD - negative CR DOUBLET/TRIPLET COMBINATION Place R/R Patients into MRD - NEGATIVE CR TR
Slide 9: Phase 1/2 Clinical Trial Emerging Clinical PK & Safety Data
Tuspetinib Phase 1/2 Clinical Trial 9 Emerging Clinical PK & Safety Data
Slide 10: APTIVATE Phase 1b/2 Expansion Trial Ongoing with Once Daily Oral Tuspetinib
APTIVATE Phase 1b/2 Expansion Trial Ongoing with Once Daily Oral Tuspetinib in R/R AML Patients with Adverse Mutations Phase 1a Dose Escalation • Doses from 20 mg to 200 mg • Once daily oral dosing of a tablet • Demonstrated safety / tolerability • Dose - related pharmacokinetics • Antileukemic acti
Slide 11: Tuspetinib Phase 1/2 Study in R/R AML Dose Escalation & Exploration Completed
11 Tuspetinib Phase 1/2 Study in R/R AML Dose Escalation & Dose Exploration Completed PART B DOSE EXPLORATION (42 Pts Dosed) PART A DOSE ESCALATION (18 Pts Dosed) Cohort 6 200 mg QD Completed Cohort 5 160 mg QD Completed Cohort 4 120 mg QD Completed Cohort 3 80 mg QD Completed Cohort 2 40 mg QD Comp
Slide 12: Phase 1/2 Study in R/R AML: Patient Profiles
Tuspetinib Phase 1/2 Study in R/R AML: Patient Profiles • As of October 6, 2022, 60 patients have been treated across 6 dose levels (20, 40, 80, 120, 160, and 200 mg) in Dose Escalation (Part A) and Dose Exploration (Part B) at 8 sites in the US and Korea , Republic of (South). • Patients treated in
Slide 13: Delivers Safety and Broad Therapeutic Window
Tuspetinib Delivers Safety and Broad Therapeutic Window Broad Therapeutic Window as a Single Agent in R/R AML Patients Data filtered through: 06OCT2022 13 Data from 2022 ASH Annual Meeting • Safety Profile Favorable to Date ― No drug - related myelosuppression ― No drug related AE of QT c prolongati
Slide 14: Clinical Pharmacodynamic Biomarkers: Hitting the Targets
Tuspetinib Phase 1/2 Clinical Trial 14 Clinical Pharmacodynamic Biomarkers │ “Hitting the Targets”
Slide 15: Tuspetinib Targets Clinically Validated Kinases in Oncogenic Signaling Pathways
Growth Factor Receptors C - KIT MUT JAK PI3K Ras RSK AKT S6K PI3K / AKT / mTOR / S6K pathway MAPK / ERK pathway mTOR MYC Cell Growth and Proliferation SYK STAT STAT JAK RAF MEK ERK NPM1c MUT Excessive levels of FLT3 ligand bind to FLT3 Receptor (WT & Mutated) SYK JNK Pwy BTK Pwy NFkB Direct Inhibiti
Slide 16: Biomarkers: Inhibition of Phospho-FLT3 and Phospho-STAT5 by Patient Plasma
0.001 - 20 0 20 40 60 80 100 % pSTAT5 Inhibition 0.001 - 20 0 20 40 60 80 100 % pFLT3 Inhibition Tuspetinib Biomarkers: Inhibition of Phosho - FLT3 and JAK/Phospho - STAT5 by Patient Plasma with a PIA Reporter Assay → Hits Targets & Only Partial Inhibition Required Abbreviation: PIA, plasma inhibito
Slide 17: Monotherapy Delivers Blast Reductions in AML Patients
Tuspetinib Monotherapy Delivers Blast Reductions in AML Patients 17
Slide 18: Waterfall Plot of Bone Marrow Blast Reductions from Baseline
18 Tuspetinib : Waterfall Plot of Bone Marrow Blast Reductions (Percent Change) from Baseline For Patients Assigned to 80 mg, 120 mg and 160 mg Dose Levels • Bone Marrow Blast Reductions • CRs achieved when blast clearance accompanied by full recovery of normal blood cells • Observed broadly across
Slide 19: Emerging Clinical Response Data Potential Superior AML Therapy
Tuspetinib Emerging Clinical Response Data Potential Superior AML Therapy 19
Slide 20: R/R AML Patients Achieving Clinical Responses with Tuspetinib Monotherapy
R/R AML Patients Achieving Clinical Responses with Tuspetinib Monotherapy Swimmer Plot of Responses Reported to Date Data from 2022 ASH Annual Meeting 20 Abbreviation: CR, complete response; CRh, complete response with partial hematologic recovery; CRi, complete response with incomplete hematologic
Slide 21: Monotherapy Clinical Responses Across R/R AML Patients with Diverse Adverse Mutations
Tuspetinib Monotherapy Clinical Responses Across R/R AML Patients with a Diversity of Adverse Mutations (Disease Heterogeneity) Patient Important Mutations FLT3 Status Dose Level Best Response Bridged to HSCT 1 TP53 WT 80mg CR No 2 NRAS RUNX1 ITD 80mg CRh Yes 3 NRAS BCOR U2AF1 SETBP1 WT 160mg CR Tx
Slide 22: Case Study Vignettes of r/r AML Patients Responding to Tuspetinib
Case Study Vignettes of r/r AML Patients Responding to Tuspetinib 22
Slide 23: Case Study: CR in FLT3-WT / NRAS-Mutant R/R AML Patient
Tuspetinib Case Study CR in FLT3 - WT / NRAS - Mutant R/R AML Patient 23 Data from 2022 ASH Annual Meeting R/R AML S2601 FLT3 - WT NRAS - mutated BCOR - mutated, U2AF1 - mutated, SETBP1 - mutated Cytogenetics: Normal Demographics 55 - year - old male Diagnosis at Study Entry Refractory AML with MDS
Slide 24: Case Study: CR in FLT3-WT / TP53-Mutant R/R AML Patient
R/R AML S2203 FLT3 - WT TP53 - Mutated Cytogenetics: Complex Karyotype Demographics 60 - year - old Male Diagnosis at Study Entry Refractory AML with MDS - related changes 70.8% bone marrow blasts at diagnosis Prior Therapies • Induction chemotherapy (cytarabine / daunorubicin) • Salvage therapy (cy
Slide 25: Case Study: CR in FLT3-ITD / Prior-FLT3i Failure R/R AML Patient
R/R AML S2220 FLT 3 - ITD Prior FLT 3 i Failure MLL - PTD , RUNX 1 - mutated Cytogenetics : Normal Demographics 49 - year - old Female Diagnosis at Study Entry Relapsed AML 66% bone marrow blasts at diagnosis Prior Therapies • Induction therapy (cytarabine / daunorubicin / midostaurin ) • Consolidat
Slide 26: Case Study: CR in FLT3-TKD / Prior FLT3i Failure R/R AML Patient
R/R AML S1301 FLT3 - TKD Prior FLT3i Failure RUNX1 - mutated, SF3B1 - mutated, RB1 - mutated Cytogenetics: Normal Demographics 67 - year - old Female Diagnosis at Study Entry Refractory AML 40% bone marrow blasts at diagnosis Prior Therapies • Induction therapy (cytarabine / daunorubicin / midostaur
Slide 27: Going Forward
Tuspetinib Going Forward 27
Slide 28: Global Dose Expansion Trial Planned to Support Registrational Trials
Tuspetinib Global Dose Expansion Trial Planned to Support Registrational Trials for Accelerated Approval and Drug Combination Trials for Broad Commercialization Doublet Combo Phase 2 Randomized Study R/R AML in 2L, FLT3 mutant – Tus vs. Tus/VEN vs. GILT Triplet Combo Phase 2 - 3 Randomized Study 1L
Slide 29: APTIVATE Trial Timeline 2023
Apr May Jun Jul Aug Sep Oct Nov Dec APTIVATE Trial delivers clinical response data to support protocol preparations and submission for initiation of a Monotherapy Ph 2 Registrational Trial to Support Accelerated Approval Ph 1/2 Dose Escalation & Exploration Trial 20, 40 , 80 , 120 , 160 , 200mg APTI
Slide 30: APTIVATE Trial Delivering Value Creating Milestones in 2023
Tuspetinib APTIVATE Trial Delivering Value Creating Milestones in 2023 2H 2023 : Potential Accelerated Approval path identified for Doublet Phase 2 Trial with Tus/Ven in R/R AML 2H 2023 : Triplet Phase 2 Trial initiation with “all oral” Tus/Ven/HMA in 1L AML Tuspetinib as Monotherapy 1Q 2023 : EOP1
Slide 31: Monotherapy for Treatment of R/R FLT3 MUT AML Patients, Prior FLT3i Failures
Tuspetinib Monotherapy for Treatment of R/R FLT3 MUT AML Patients │ Prior FLT3i Failures 31
Slide 32: Likely Bar for Tuspetinib Accelerated Approval in R/R FLT3 MUT AML
Likely Bar for Tuspetinib Accelerated Approval in R/R FLT3 MUT AML│Prior FLT3i Failures 32 • Gilteritinib FLT3i Approved with CR/CRh = 21% in 2L FLT3 MUT AML Patients • FDA Review: Interim CR/CRh = 21% based on data from the First Interim Analysis of the ADMIRAL trial • Gilteritinib approved • USPI
Slide 33: Safely Delivers Monotherapy Responses Across Diverse AML Populations
Tuspetinib Safely Delivers Monotherapy Responses Across Diverse AML Populations Example AML Populations with Adverse Mutations • TP53 - mutant • RAS - mutant • NPM1 - mutant - /+ FLT3 - mutant • FLT3 - mutant • FLT3 - mutant failed prior FLT3i therapy % of AML Patients 8 - 10% 15 - 40% 30% / 15% 25
Slide 34: Tuspetinib Best in Class TKI for AML: Comparison to Other Agents
TUSPETINIB Best in Class TKI for AML : Targets FLT3 + SYK + JAK - 1/2 + C - KIT Comparison to Other Approved or Investigational Agents Tuspetinib Gilteritinib Quizartinib Emavusertib Revumenib Ziftomenib Lanraplenib MOA / Targets SYK, JAK1/2 FLT3 ITD/ TKD/WT c - KIT MUT FLT3 ITD/TKD FLT3 ITD IRAK4/F
Slide 35: Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Hematologic Malignancies
Precision Oncology Company Developing Oral Kinase Inhibitors to Treat Life - threatening Hematologic Malignancies Tuspetinib │ Safely Treats AML Disease Heterogeneity │ Orphan Drug Status │ Fast Track Status Disease heterogeneity is the greatest obstacle to the effective treatment of AML Tuspetinib
Slide 36: Aptose Biosciences
APTGSE BIOSCIENCES
Aptose Biosciences — Investor Presentation (January 2023) on 6ix